Chronic Daily Headache
Posted on December 19 2023,
Definition
Chronic daily headache (CDH) is not a formal diagnosis in the International Classification of Headache Disorders, 3rd edition (ICHD-3). Rather, it is an umbrella term used to describe a range of primary and secondary headache disorders characterized by duration and/or frequency depending on the specific headache type. For example, some long CDH subtypes (see below) must persist for 15 or more days per month for at least 3 months while shorter duration CDH subtypes- e.g., cluster or paroxysmal hemicrania- must persist for at least one year without remission or with remissions lasting less than three months.
So while not a distinct diagnosis itself, chronic daily headache encompasses a group of headache disorders marked by extremely frequent headache attacks.
Epidemiology
- CDH has an estimated worldwide prevalence of around 4% in adults. It is 2-3 times more common in females.
- The most common headache types underlying CDH are chronic tension-type headache and chronic migraine. CDH results in substantial disability and economic costs.
CDH Subtypes
The main CDH subtypes of long duration (≥4 hours per headache) are:
- Chronic migraine: evolution from episodic migraines, migraine features on ≥ 8 days/month
- Chronic tension-type headache: pressing, bilateral pain without migraine features
- Medication overuse/adaptation headache: worsening headaches due to overuse of acute medications
- Hemicrania continua: unilateral, moderate pain with cranial autonomic symptoms
- New daily persistent headache: daily headaches without characteristic features
https://www.cerebraltorque.com/blogs/migrainescience/new-daily-persistent-headache-ndph
Other shorter duration headaches (<4 hours per headache) can also be chronic, like:
- Chronic cluster headache
- Chronic paroxysmal hemicrania
- Short-lasting unilateral neuralgiform headache attacks
https://www.cerebraltorque.com/blogs/migrainescience/trigeminal-autonomic-cephalalgias
- Hypnic headache
https://www.cerebraltorque.com/blogs/migrainescience/hypnic-headache
- Primary stabbing headache
Diagnosis
CDH diagnosis depends on meeting criteria for specific headache types after excluding secondary causes.
- Most patients have an unrevealing history and normal neurological exam.
- Further diagnostic testing is based on the presence of "red flags" like:
https://www.cerebraltorque.com/blogs/migrainescience/do-i-need-neuroimaging-for-my-headache
- Differential includes secondary headaches from infections, mass lesions, vascular disorders, etc. See link above for more information.
Treatment
Treatment focuses on the specific CDH diagnosis and preventing medication overuse/adaptation headache.
- Chronic migraine: preventives, avoidance of triggers, acute medications, assess for medication overuse/adaptation headache.
Acute: https://www.cerebraltorque.com/blogs/migrainescience/acute-migraine-treatment-cheat-sheet
Prevention: https://www.cerebraltorque.com/blogs/migrainescience/chronic-migraine-preventives
- Chronic tension-type headache: preventives, behavioral and physical therapy
Acute: https://www.cerebraltorque.com/blogs/migrainescience/acute-treament-of-tension-type-headache-tth
Prevention: https://www.cerebraltorque.com/blogs/migrainescience/tension-type-headache-preventive-treatment
- Medication overuse/adaptation headache: Establish preventives
- Other CDH subtypes have more specific treatments e.g. indomethacin for hemicrania continua
https://www.cerebraltorque.com/blogs/migrainescience/trigeminal-autonomic-cephalalgias
Wed, Dec 17, 25
Migraine Management During Pregnancy, Breastfeeding, and Pregnancy Planning
This guide provides comprehensive, evidence-based recommendations for migraine management throughout the reproductive journey.
Read MoreMon, Nov 17, 25
Migraine Research - During the week of my absence.
Migraine Research - During the week of my absence. The Association Between Insomnia and Migraine Disability and Quality of Life This study examined how insomnia severity relates to migraine disability...
Read MoreSat, Nov 01, 25
Anti-CGRP Monoclonal Antibody Migraine Treatment: Super-Responders and Absolute Responders and When to Expect Results
Anti-CGRP monoclonal antibodies achieved 70% super-response and 23% complete migraine freedom in a one-year study. Most dramatic improvements occurred after 6 months of treatment. For patients with chronic or high-frequency...
Read More
